Lisa M Kalisch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/30474/publications.pdf

Version: 2024-02-01

84 papers

1,389 citations

394421 19 h-index 33 g-index

86 all docs 86 docs citations

86 times ranked 1851 citing authors

#	Article	IF	CITATIONS
1	The Risk of Preoperative Central Nervous System-Acting Medications on Delirium Following Hip or Knee Surgery: A Matched Case-Control Study. Drug Safety, 2022, 45, 75-82.	3.2	3
2	Implementation and Evaluation of a Digitally Enabled Precision Public Health Intervention to Reduce Inappropriate Gabapentinoid Prescription: Cluster Randomized Controlled Trial. Journal of Medical Internet Research, 2022, 24, e33873.	4.3	5
3	The Extent of Medication-Related Hospital Admissions in Australia: A Review from 1988 to 2021. Drug Safety, 2022, 45, 249-257.	3.2	32
4	The effects of anticholinergic medications on cognition in children: a systematic review and meta-analysis. Scientific Reports, 2021, 11, 219.	3.3	9
5	Post-market utilization patterns of Alzheimer's disease treatments in South Korea: comparison with countries with universal health coverage. European Journal of Clinical Pharmacology, 2021, 77, 921-929.	1.9	5
6	Prevalence of multiple risk factors for poor outcomes associated with COVID-19 among an elderly Australian population. Australian Journal of General Practice, 2021, 50, 84-89.	0.8	2
7	Variation in health service use by veterans with an accepted disability of post-traumatic stress disorder who had a service record post 1975: a cluster analysis. BMJ Military Health, 2021, , bmjmilitary-2020-001456.	0.9	O
8	Medicationâ€related hospital admissions in aged care residents. Australasian Journal on Ageing, 2021, 40, .	0.9	2
9	Evaluation of Renal Function Testing in Older Australian Veterans Dispensed Medicines that Require Renal Function Monitoring. Drugs and Aging, 2021, 38, 995-1002.	2.7	O
10	Patient-Reported Questionnaires to Identify Adverse Drug Reactions: A Systematic Review. International Journal of Environmental Research and Public Health, 2021, 18, 11877.	2.6	5
11	Generating Real-World Evidence on the Quality Use, Benefits and Safety of Medicines in Australia: History, Challenges and a Roadmap for the Future. International Journal of Environmental Research and Public Health, 2021, 18, 13345.	2.6	11
12	Rationalisation of polypharmacy in practice: a survey of physicians and pharmacists. Journal of Pharmacy Practice and Research, 2020, 50, 233-241.	0.8	3
13	Uncertain Association Between Benzodiazepine Use and the Risk of Dementia: A Cohort Study. Journal of the American Medical Directors Association, 2020, 21, 201-211.e2.	2.5	20
14	Reducing medicine-induced deterioration and adverse reactions (ReMInDAR) trial: study protocol for a randomised controlled trial in residential aged-care facilities assessing frailty as the primary outcome. BMJ Open, 2020, 10, e032851.	1.9	13
15	Predictors of Mortality in the Older Population: The Role of Polypharmacy and Other Medication and Chronic Disease-Related Factors. Drugs and Aging, 2020, 37, 767-776.	2.7	11
16	Potentially inappropriate medication use and related hospital admissions in aged care residents: The impact of dementia. British Journal of Clinical Pharmacology, 2020, 86, 2414-2423.	2.4	9
17	Use of health and support services by people living with dementia in the community setting. Australasian Journal on Ageing, 2020, 39, 341-349.	0.9	3
18	Use of analgesics following rescheduling of codeine in Australia: An interrupted time series analysis in the veteran population. International Journal of Drug Policy, 2020, 81, 102767.	3.3	7

#	Article	IF	CITATIONS
19	We need to do better: most people with dementia living in aged care facilities use antipsychotics for too long, for off-label indications and without documented consent. International Psychogeriatrics, 2020, 32, 299-302.	1.0	5
20	Detecting Medicine Safety Signals Using Prescription Sequence Symmetry Analysis of a National Prescribing Data Set. Drug Safety, 2020, 43, 787-795.	3.2	8
21	Predictors of unplanned hospitalisation in the older population: The role of polypharmacy and other medication and chronic diseaseâ€related factors. Australasian Journal on Ageing, 2020, 39, e436-e446.	0.9	2
22	Risk of chronic opioid use in older persons with pre-existing anxiety. Journal of Opioid Management, 2020, 16, 59-66.	0.5	1
23	Comorbidities in an Australian sample of chronic and new opioid users. Journal of Opioid Management, 2020, 16, 103-110.	0.5	0
24	A cross-sectional assessment of the relationship between sedative medication and anticholinergic medication use and the movement behaviour of older adults living in residential aged care. PeerJ, 2020, 8, e9605.	2.0	1
25	Impact of a patient-specific national programme aimed at increasing the use of emollient moisturisers to reduce the risk of skin tears: a longitudinal cohort study. BMJ Open, 2020, 10, e039579.	1.9	0
26	Impact of a patient-specific national programme aimed at increasing the use of emollient moisturisers to reduce the risk of skin tears: a longitudinal cohort study. BMJ Open, 2020, 10, e039579.	1.9	0
27	Implementation of medication-related indicators of potentially preventable hospitalizations in a national chronic disease management program for older patients with multimorbidity. International Journal for Quality in Health Care, 2019, 31, 133-139.	1.8	3
28	Reduction in Use of Risperidone for Dementia in Australia Following Changed Guidelines. Pharmacy (Basel, Switzerland), 2019, 7, 100.	1.6	5
29	Initiation and continuation of antipsychotic medicines in older people following non-psychiatric hospital admission. International Journal of Clinical Pharmacy, 2019, 41, 1341-1347.	2.1	4
30	Medication Use for Comorbidities in People with Alzheimer's Disease: An Australian Populationâ€Based Study. Pharmacotherapy, 2019, 39, 1146-1156.	2.6	17
31	Use of medicines that may precipitate delirium prior to hospitalisation in older Australians with delirium: An observational study. Australasian Journal on Ageing, 2019, 38, 124-131.	0.9	8
32	Potentially inappropriate prescribing in people with dementia: An Australian populationâ€based study. International Journal of Geriatric Psychiatry, 2019, 34, 1498-1505.	2.7	16
33	Prevalence and Duration of Use of Medicines Recommended for Short-Term Use in Aged Care Facility Residents. Pharmacy (Basel, Switzerland), 2019, 7, 55.	1.6	6
34	Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study. BMJ Open, 2019, 9, e026486.	1.9	8
35	Potentially inappropriate prescribing before and after initiation of medicines for dementia: An Australian populationâ€based study. Geriatrics and Gerontology International, 2019, 19, 654-659.	1.5	4
36	Analysis of anticholinergic and sedative medicine effects on physical function, cognitive function, appetite and frailty: a cross-sectional study in Australia. BMJ Open, 2019, 9, e029221.	1.9	23

#	Article	IF	CITATIONS
37	Adaptation of potentially preventable medication-related hospitalisation indicators for indigenous populations in Australia using a modified Delphi technique. BMJ Open, 2019, 9, e031369.	1.9	9
38	The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System. BMJ Open, 2018, 8, e021122.	1.9	166
39	The Uncertainty of the Association Between Proton Pump Inhibitor Use and the Risk of Dementia: Prescription Sequence Symmetry Analysis Using a Korean Healthcare Database Between 2002 and 2013. Drug Safety, 2018, 41, 615-624.	3.2	23
40	Do Risk Prediction Models for Postoperative Delirium Consider Patients' Preoperative Medication Use?. Drugs and Aging, 2018, 35, 213-222.	2.7	7
41	Knowledge of Australian hospital pharmacists regarding delirium in elderly patients. Journal of Pharmacy Practice and Research, 2018, 48, 116-123.	0.8	3
42	Antipsychotic polypharmacy in older Australians. International Psychogeriatrics, 2018, 30, 539-546.	1.0	6
43	A narrative review of problems with medicines use in people with dementia. Expert Opinion on Drug Safety, 2018, 17, 825-836.	2.4	17
44	Reducing hypnotic use in insomnia management among Australian veterans: results from repeated national interventions. BMC Health Services Research, 2018, 18, 626.	2.2	7
45	Sustaining practice change in health care: the impact of a national quality improvement program on the uptake of collaborative medicines reviews. Journal of Pharmacy Practice and Research, 2018, 48, 222-230.	0.8	9
46	Patient-specific prescriber feedback can increase the rate of osteoporosis screening and treatment: results from two national interventions. Archives of Osteoporosis, 2017, 12, 17.	2.4	7
47	Posttraumatic Stress Disorder, Antipsychotic Use and Risk of Dementia in Veterans. Journal of the American Geriatrics Society, 2017, 65, 1521-1526.	2.6	18
48	Use of proton pump inhibitors among older Australians: national quality improvement programmes have led to sustained practice change. International Journal for Quality in Health Care, 2017, 29, 75-82.	1.8	30
49	Current practice and opinions of hospital pharmacists regarding their role in the screening, prevention and treatment of delirium. International Journal of Clinical Pharmacy, 2017, 39, 1194-1200.	2.1	6
50	Preoperative medication use and postoperative delirium: a systematic review. BMC Geriatrics, 2017, 17, 298.	2.7	75
51	Apixaban, concomitant medicines and spontaneous reports of haemorrhagic events. Therapeutic Advances in Drug Safety, 2017, 8, 157-164.	2.4	8
52	Central Nervous System-Acting Medicines and Risk of Hospital Admission for Confusion, Delirium, or Dementia. Journal of the American Medical Directors Association, 2016, 17, 530-534.	2.5	7
53	Increased risk of hospital admission for dehydration or heat-related illness after initiation of medicines: a sequence symmetry analysis. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 503-507.	1.5	21
54	Sequence Symmetry Analysis as a Signal Detection Tool for Potential Heart Failure Adverse Events in an Administrative Claims Database. Drug Safety, 2016, 39, 347-354.	3.2	20

#	Article	IF	CITATIONS
55	Commitment questions targeting patients promotes uptake of under-used health services: Findings from a national quality improvement program in Australia. Social Science and Medicine, 2015, 145, 1-6.	3.8	12
56	Suboptimal medicationâ€related quality of care preceding hospitalisation of older patients. Medical Journal of Australia, 2015, 203, 220-220.	1.7	8
57	Association between Ophthalmic Timolol and Hospitalisation for Bradycardia. Journal of Ophthalmology, 2015, 2015, 1-6.	1.3	15
58	Response to Lertxundi and Colleagues. Journal of the American Geriatrics Society, 2015, 63, 1054-1055.	2.6	1
59	An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran. Pharmacoepidemiology and Drug Safety, 2015, 24, 399-405.	1.9	22
60	Multiple Anticholinergic Medication Use and Risk of Hospital Admission for Confusion or Dementia. Journal of the American Geriatrics Society, 2014, 62, 1916-1922.	2.6	100
61	Ranibizumab and Risk of Hospitalisation for Ischaemic Stroke and Myocardial Infarction in Patients with Age-Related Macular Degeneration: A Self-Controlled Case-Series Analysis. Drug Safety, 2014, 37, 1021-1027.	3.2	18
62	Development of evidence-based Australian medication-related indicators of potentially preventable hospitalisations: a modified RAND appropriateness method. BMJ Open, 2014, 4, e004625.	1.9	28
63	A Cross-Country Comparison of Rivaroxaban Spontaneous Adverse Event Reports and Concomitant Medicine Use with the Potential to Increase the Risk of Harm. Drug Safety, 2014, 37, 1029-1035.	3.2	17
64	Comparing Time to Adverse Drug Reaction Signals in a Spontaneous Reporting Database and a Claims Database: A Case Study of Rofecoxib-Induced Myocardial Infarction and Rosiglitazone-Induced Heart Failure Signals in Australia. Drug Safety, 2014, 37, 53-64.	3.2	26
65	Risk of Medicationâ€Associated Initiation of Oxybutynin in Elderly Men and Women. Journal of the American Geriatrics Society, 2014, 62, 690-695.	2.6	17
66	Association Between Use of Multiple Psychoactive Medicines and Hospitalization for Falls: Retrospective Analysis of a Large Healthcare Claim Database. Drug Safety, 2014, 37, 529-535.	3.2	33
67	Bridging evidence-practice gaps: improving use of medicines in elderly Australian veterans. BMC Health Services Research, 2013, 13, 514.	2.2	32
68	The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiology and Drug Safety, 2013, 22, 496-502.	1.9	57
69	Home Medicines Reviews: Extent of Uptake by Highâ€Risk Veterans. Journal of Pharmacy Practice and Research, 2013, 43, 182-186.	0.8	8
70	The Detection of Adverse Events in Randomized Clinical Trials: Can we Really Say New Medicines are Safe?. Current Drug Safety, 2013, 8, 104-113.	0.6	13
71	Prevalence of preventable medication-related hospitalizations in Australia: an opportunity to reduce harm. International Journal for Quality in Health Care, 2012, 24, 239-249.	1.8	61
72	Managing Glaucoma in those with Co-morbidity: Not as Easy as it Seems. Ophthalmic Epidemiology, 2012, 19, 74-82.	1.7	32

#	Article	IF	CITATIONS
73	Prescriber Feedback to Improve Quality Use of Medicines among Older People: the Veterans' MATES Program. Journal of Pharmacy Practice and Research, 2011, 41, 316-319.	0.8	12
74	Continuity of care: when do patients visit community healthcare providers after leaving hospital?. Internal Medicine Journal, 2011, 41, 662-667.	0.8	34
75	The prescribing cascade. Australian Prescriber, 2011, 34, 162-166.	1.0	58
76	Pharmaceutical brand substitution in Australia: Identifying factors associated with having multiple brand substitutions. International Journal of Pharmacy Practice, 2010, 17, 339-344.	0.6	0
77	Use of health services and medicines amongst Australian war veterans: a comparison of young elderly, near centenarians and centenarians. BMC Geriatrics, 2010, 10, 83.	2.7	11
78	Prevalence of potentially hazardous drug interactions amongst Australian veterans. British Journal of Clinical Pharmacology, 2010, 70, 252-257.	2.4	48
79	Improving heart failure outcomes with pharmacist–physician collaboration: how close are we?. Future Cardiology, 2010, 6, 255-268.	1.2	11
80	Pharmaceutical brand substitution in Australia: identifying factors associated with having multiple brand substitutions. International Journal of Pharmacy Practice, 2009, 17, 339-344.	0.6	0
81	Brand substitution or multiple switches per patient? An analysis of pharmaceutical brand substitution in Australia. Pharmacoepidemiology and Drug Safety, 2008, 17, 620-625.	1.9	11
82	Do Pharmacists Adhere to Brand Substitution Guidelines? The Example of Simvastatin. Journal of Pharmacy Practice and Research, 2007, 37, 292-294.	0.8	0
83	Pharmaceutical brand substitution in Australia – are there multiple switches per prescription?. Australian and New Zealand Journal of Public Health, 2007, 31, 348-352.	1.8	13
84	Use of medicines in adults with autism spectrum disorder in Australia. Journal of Pharmacy Practice and Research, 0 , , .	0.8	1